BR0116206A - Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos - Google Patents

Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos

Info

Publication number
BR0116206A
BR0116206A BR0116206-3A BR0116206A BR0116206A BR 0116206 A BR0116206 A BR 0116206A BR 0116206 A BR0116206 A BR 0116206A BR 0116206 A BR0116206 A BR 0116206A
Authority
BR
Brazil
Prior art keywords
peptide
metabolic disorders
treatment
agonists
pyy
Prior art date
Application number
BR0116206-3A
Other languages
English (en)
Inventor
Richard A Pittner
Andrew A Young
James R Paterniti
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22971453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0116206(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of BR0116206A publication Critical patent/BR0116206A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

"PEPTìDEO YY E AGONISTAS DE PEPTìDEO YY PARA TRATAMENTO DE DISTúRBIOS METABóLICOS". A invenção refere-se a métodos e composições para tratar distúrbios metabólicos tais como obesidade, diabetes, e risco cardiovascular aumentado, compreendendo administar um quantidade terapeuticamente eficaz de um PYY ou um agonista de PYY.
BR0116206-3A 2000-12-14 2001-12-14 Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos BR0116206A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25621600P 2000-12-14 2000-12-14
PCT/US2001/048336 WO2002047712A2 (en) 2000-12-14 2001-12-14 Peptide yy and peptide yy agonists for treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
BR0116206A true BR0116206A (pt) 2003-12-23

Family

ID=22971453

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116206-3A BR0116206A (pt) 2000-12-14 2001-12-14 Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos

Country Status (12)

Country Link
US (3) US8273713B2 (pt)
EP (2) EP1349563B1 (pt)
JP (1) JP2004515533A (pt)
CN (1) CN1568195B (pt)
AT (1) ATE450269T1 (pt)
AU (1) AU2002230843B8 (pt)
BR (1) BR0116206A (pt)
CA (1) CA2431800C (pt)
DE (1) DE60140693D1 (pt)
MX (1) MXPA03005388A (pt)
RU (1) RU2275207C2 (pt)
WO (1) WO2002047712A2 (pt)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
DE60230818D1 (de) * 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
CA2461454A1 (en) 2001-09-24 2003-04-03 Oregon Health And Science University Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
AU2003201998C1 (en) * 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
EA008829B1 (ru) 2002-12-17 2007-08-31 Нэстек Фармасьютикал Кампани Инк. Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1583549A4 (en) * 2003-01-17 2006-10-04 Sod Conseils Rech Applic YY PEPTIDE ANALOGS
SI1620118T1 (sl) * 2003-04-08 2014-11-28 Yeda Research And Development Co., Ltd. Reverzibilna pegilirana zdravila
ES2425221T3 (es) 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
WO2005053726A1 (en) * 2003-11-25 2005-06-16 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
CA2555894A1 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CA2849552A1 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
BRPI0507585A (pt) * 2004-03-17 2007-07-03 7Tm Pharmas As agonistas seletivos do receptor y2 para intervenções terapêuticas
BRPI0508861A (pt) * 2004-03-17 2007-08-28 7Tm Pharmas As agonistas do receptor y2/y4 seletivo para intervenções terapêuticas
CN1933848A (zh) * 2004-03-17 2007-03-21 7Tm制药联合股份有限公司 用于治疗性干预的y2选择性受体激动剂
ES2586423T3 (es) * 2004-05-14 2016-10-14 Emisphere Technologies, Inc. Compuestos de aril cetona y composiciones para administrar principios activos
CA2565188C (en) 2004-05-14 2014-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2005110457A2 (en) * 2004-05-18 2005-11-24 Aditech Pharma Ab Treatment of eating disorders and induction of lipolysis
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
US9399054B2 (en) * 2004-07-12 2016-07-26 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
EP1645877A1 (en) * 2004-10-08 2006-04-12 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for providing a insulin resistance biomarker profile of one or more lipids
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
EP3000826A1 (en) 2004-12-13 2016-03-30 Amylin Pharmaceuticals, LLC Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP4584331B2 (ja) * 2005-03-11 2010-11-17 インデバス ファーマシューティカルズ、インク． オクトレオチドの放出制御製剤
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP1922336B1 (en) * 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
BRPI0520563A2 (pt) 2005-09-21 2009-05-19 7Tm Pharma As agonistas de receptores y4 seletivos para intervenções terapêuticas
AU2005337101A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
BRPI0708264A2 (pt) 2006-02-23 2011-05-24 Pfizer Ltd piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina
EA200870365A1 (ru) * 2006-03-23 2009-02-27 Амилин Фармасьютикалз, Инк. Эндотелин и агонисты рецепторов к эндотелину в лечении заболеваний обмена веществ
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
AU2007320906A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
WO2008062276A2 (en) * 2006-11-20 2008-05-29 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
MX2010011845A (es) * 2008-05-16 2010-11-22 Novo Nordisk As Agonistas del receptor y2 y/o y4 de larga accion.
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
UA104866C2 (uk) 2008-06-25 2014-03-25 Ендо Фармас'Ютікалз Солюшнз Інк. Імплантат октреотиду, який містить вивільняючу речовину
JP5622725B2 (ja) 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． エキセナチド及び他のポリペプチド類の持続的送達
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010015972A1 (en) 2008-08-06 2010-02-11 Pfizer Limited Diazepine and diazocane compounds as mc4 agonists
US9492505B2 (en) 2009-01-21 2016-11-15 University Of Florida Research Foundation, Inc. Satiation peptide administration
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK3326620T3 (da) 2010-12-16 2020-05-25 Novo Nordisk As Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9346852B2 (en) 2011-03-14 2016-05-24 Bristol-Myers Scuibb Company Substituted adipic acid amides and uses thereof
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
AU2013234496B2 (en) 2012-03-22 2017-07-27 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
CN104684576B (zh) 2012-06-04 2019-08-06 奥普科生物制品有限公司 聚乙二醇化的oxm变体
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
EP3068421B1 (en) 2013-11-15 2019-04-17 Novo Nordisk A/S Selective pyy compounds and uses thereof
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
CN107849110B (zh) * 2015-06-12 2021-11-26 诺和诺德股份有限公司 选择性pyy化合物及其用途
US10224727B2 (en) * 2015-06-30 2019-03-05 Dong-Sheng Li Multi-functional hub integrated with AC power supply
US11311633B2 (en) 2016-04-16 2022-04-26 University Of Florida Research Foundation, Incorporated Satiation peptides for weight loss and altered taste sensitivity
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
AU2019211322A1 (en) 2018-01-23 2020-07-23 Gila Therapeutics, Inc. Peptide YY pharmaceutical formulations, compositions, and methods
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
GB2573145A (en) * 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
TW202208410A (zh) 2018-11-01 2022-03-01 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4701441A (en) * 1985-02-11 1987-10-20 University Of Florida Methods and compositions for stimulation of appetite
US4891357A (en) 1985-02-11 1990-01-02 University Of Florida Methods and compositions for stimulation of appetite
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4839343A (en) * 1987-03-13 1989-06-13 Debiopharm, S.A. Preparation containing hexatriacontapeptides and methods of use
WO1989001967A1 (en) 1987-09-03 1989-03-09 Brown University Research Foundation Blood purification with cultured renal cells
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
WO1990015637A2 (en) 1989-06-21 1990-12-27 Brown University Research Foundation Neurological therapy system
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US6391343B1 (en) * 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
WO1994016101A2 (en) 1993-01-07 1994-07-21 Koester Hubert Dna sequencing by mass spectrometry
JPH08510205A (ja) 1993-03-29 1996-10-29 ユニバーシティ オブ シンシナティ Ｙｙペプチドのアナログとその用途
US5498531A (en) * 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5545549A (en) * 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5696093A (en) * 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en) * 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5912227A (en) 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
US20020094346A1 (en) * 1995-05-17 2002-07-18 M. D. Henry C. Lin Method and compositions for improving digestion and absorption in the small intestine
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6355478B1 (en) * 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor
US5686511A (en) 1996-06-28 1997-11-11 The Valspar Corporation Esterifying epoxy resin with carboxyl polymer and quenching
ES2425559T5 (es) 1997-01-07 2018-02-02 Amylin Pharmaceuticals, Llc Composiciones farmacéuticas que comprenden las exendinas y los agonistas de las mismas
CA2251368A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
DE69812096T2 (de) * 1997-04-23 2003-10-30 Banyu Pharma Co Ltd Neuropeptid y rezeptorantagonisten
PT1019077E (pt) 1997-08-08 2008-02-21 Amylin Pharmaceuticals Inc Novos compostos agonistas de exendina
JP3036480B2 (ja) 1997-08-25 2000-04-24 日本電気株式会社 バーコード読取装置およびその焦点制御方法
WO1999015516A1 (fr) 1997-09-25 1999-04-01 Banyu Pharmaceutical Co., Ltd. Nouveaux antagonistes des recepteurs de neuropeptides y
DK1032587T4 (da) 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonist-forbindelser
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
DE69943039D1 (de) 1998-02-13 2011-01-27 Amylin Pharmaceuticals Inc Neue verbindungen mit gemischter amylin aktivität
US6013622A (en) 1998-04-15 2000-01-11 Nutriceutical Technology Corporation Method of regulating appetite and metabolism
EP1932535A3 (en) * 1998-07-31 2008-10-29 Novo Nordisk A/S Stimulation of beta cell profileration
US20020015950A1 (en) * 1999-07-07 2002-02-07 Karen Anne Jones Atherosclerosis-associated genes
DK1189629T3 (da) * 1999-02-10 2011-01-03 Curis Inc Peptid YY (PYY) til behandling af glucosestofskiftesygdomme
US7745216B2 (en) * 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
EP1177172A1 (en) * 1999-05-05 2002-02-06 Ortho-McNeil Pharmaceutical, Inc. 3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6734166B1 (en) * 2000-02-08 2004-05-11 North Carolina State University Method of reducing aluminum levels in the central nervous system
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
DE60230818D1 (de) 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
AU2003243545A1 (en) 2002-06-14 2003-12-31 Amylin Pharmaceuticals, Inc. Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof

Also Published As

Publication number Publication date
CN1568195A (zh) 2005-01-19
WO2002047712A2 (en) 2002-06-20
AU2002230843B2 (en) 2006-10-19
CA2431800A1 (en) 2002-06-20
WO2002047712A3 (en) 2002-09-06
JP2004515533A (ja) 2004-05-27
MXPA03005388A (es) 2003-09-25
US8273713B2 (en) 2012-09-25
EP2123293A3 (en) 2010-09-08
AU2002230843B8 (en) 2007-05-17
EP2123293A2 (en) 2009-11-25
EP1349563A2 (en) 2003-10-08
US20020141985A1 (en) 2002-10-03
CA2431800C (en) 2014-07-08
AU3084302A (en) 2002-06-24
US20140135261A1 (en) 2014-05-15
ATE450269T1 (de) 2009-12-15
RU2275207C2 (ru) 2006-04-27
EP1349563B1 (en) 2009-12-02
US20130023466A1 (en) 2013-01-24
CN1568195B (zh) 2011-03-02
DE60140693D1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
BR0116206A (pt) Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
EA200500776A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АГОНИСТ β3-АДРЕНОРЕЦЕПТОРА И ИНГИБИТОР ОБРАТНОГО ЗАХВАТА СЕРОТОНИНА И/ИЛИ НОРЭПИНЕФРИНА, И ЕЕ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ ФУНКЦИИ МОЧЕВОГО ПУЗЫРЯ
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
BR0214962A (pt) Composição para tratar distúrbios neurocerebrovasculares
PL374865A1 (en) Treatment of tnf alpha related disorders
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
EP1007556A4 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
PA8467401A1 (es) Procedimiento para tratar la insuficiencia cardiaca
TWI367751B (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
IS8162A (is) Aðferð til að meðhöndla eða fyrirbyggja neðri þvagvegaeinkenni
ATE263572T1 (de) Verwendung von gastrin fragmenten oder sythetischen analogen von gastrin zur herstellung eines arzneimittels zur behandlung der helicobacter pylori assozierten störungen
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
WO2002064160A3 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
WO2001080894A3 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
DK1342410T3 (da) Anvendelse af en galaninagonist til fremstilling af et medikament til forbedring af hukommelse og andre kognitive funktioner
PT980253E (pt) Somatostatina e agonistas de somatostatina para tratar a insensibilidade a insulina e a sindrome x

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: AMYLIN PHARMACEUTICALS, LLC (US)

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA PHARMACEUTICALS LP (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: AMYLIN PHARMACEUTICALS, INC. (US) , ASTRAZENECA PH

Free format text: RETIFICACAO DO DESPACHO (25.1) TRANSFERENCIA DEFERIDA PUBLICADO NA RPI NO 2224, DE 20/08/2013, QUANTO AO ITEM (71) NOME DO DEPOSITANTE . ONDE SE LE: ASTRAZENECA PHARMACEUTICALS LP LEIA-SE: AMYLIN PHARMACEUTICALS, LLC E ASTRAZENECA PHARMACEUTICALS LP